Pfizer is significantly expanding its presence in the obesity treatment market by acquiring Metsera for $4.9 billion, offering a substantial premium per share. Metsera, while lacking marketed products, boasts several promising clinical programs. This strategic move reflects the surging demand for obesity treatments, currently dominated by Eli Lilly and Novo Nordisk. Post navigation India’s exports to US plunge! Not just goods hit by Trump’s 50% tariffs, even smartphones see ‘alarming’ dip; what’s happening? Talent tide turns: US H-1B visa fee shock may fuel reverse brain drain; Indian startups eye AI boost
